RonaldBMossMD

PubMed

• 4 citations
  Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients.
  Kavita Mathi, Yael Rosenberg-Hasson, Holden T. Maecker, Dennis J. Carlo, Ronald B. Moss> ;Clinical Immunology. 2021 Aug 21
• 21 citations
  Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level.
  Ronald B. Moss, Meghan McCabe Pryor, Rebecca Baillie, Katherine Kudrycki, Christina M. Friedrich, Michael J. Reed, Dennis J. Carlo> ;Plos One. 2020 Jun 16
• An open-label, randomized, single-dose, two-period, two-treatment crossover bioavailability study comparing 5 mg/0.5 mL of intramuscular naloxone hydrochloride to 2 mg...
  Ronald B. Moss, Fiona Carleton, Charles P. Lollo, Dennis J. Carlo> ;Journal of Opioid Management. 2020 May 1
• 6 citations
  The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys.
  Peter J. H. Scott, Robert A. Koeppe, Xia Shao, Melissa E. Rodnick, Alexandra R. Sowa, Bradford D. Henderson, Jenelle Stauff, Phillip S. Sherman, Janna Arteaga, Dennis ...> ;Molecules. 2020 Mar 17
• 84 citations
  Higher doses of naloxone are needed in the synthetic opioid era
  Ronald B. Moss, Dennis J. Carlo> ;Substance Abuse Treatment, Prevention, and Policy. 2019 Feb 18
• 1 citations
  Human factors study of a newly approved prefilled syringe of epinephrine for the treatment of anaphylaxis.
  Ronald B. Moss, Thomas Moll, Karen Daniels, Dennis J. Carlo> ;Allergy and Asthma Proceedings. 2018 Sep 1
• 3 citations
  Human factors study in untrained adolescents comparing a recently approved single-dose epinephrine prefilled syringe with an approved autoinjector.
  Ronald B. Moss, Karen Daniels, Thomas Moll, Dennis J. Carlo> ;Annals of Allergy, Asthma & Immunology. 2018 Feb 27
• 27 citations
  The use of sialidase therapy for respiratory viral infections.
  John M. Nicholls, Ronald B. Moss, Stuart M. Haslam> ;Antiviral Research. 2013 Jun 1
• 102 citations
  A Phase II Study of DAS181, a Novel Host Directed Antiviral for the Treatment of Influenza Infection
  Ronald B. Moss, Carrie Hansen, Rebecca L. Sanders, Stephen Hawley, Tiejun Li, Roy T. Steigbigel> ;The Journal of Infectious Diseases. 2012 Dec 15
• 40 citations
  Treatment of Parainfluenza 3 Infection With DAS181 in a Patient After Allogeneic Stem Cell Transplantation
  Yi Bin Chen, Jessica Driscoll, Steven L. McAfee, Thomas R. Spitzer, Eric S. Rosenberg, Rebecca L. Sanders, Ronald B. Moss, Fang Fang, Francisco M. Marty> ;Clinical Infectious Diseases. 2011 Oct 1
• 6 citations
  Perspective: emerging challenges in the treatment of influenza and parainfluenza in transplant patients.
  Ronald B. Moss, Roy T. Steigbigel, Rebecca L. Sanders, Fang Fang> ;Advances in Virology. 2011 Jul 7
• 53 citations
  Targeting pandemic influenza: a primer on influenza antivirals and drug resistance
  Ronald B. Moss, Richard T. Davey, Roy T. Steigbigel, Fang Fang> ;The Journal of Antimicrobial Chemotherapy. 2010 Jun 1
• 105 citations
  Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
  Larry R. Smith, Mary K. Wloch, Ming Ye, Luane Reyes, Souphaphone Boutsaboualoy, Casey E. Dunne, Jennifer A. Chaplin, Denis Rusalov, Alain Rolland, Cindy L. Fisher, Moh...> ;Vaccine. 2010 Mar 16
• 81 citations
  Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.
  Gallen B. Triana-Baltzer, Larisa V. Gubareva, John M. Nicholls, Melissa B. Pearce, Vasiliy P. Mishin, Jessica A. Belser, Li-Mei Chen, Renee W. Y. Chan, Michael C. W. C...> ;Plos One. 2009 Nov 6
• 57 citations
  Inhibition of Neuraminidase Inhibitor-Resistant Influenza Virus by DAS181, a Novel Sialidase Fusion Protein
  Gallen B. Triana-Baltzer, Larisa V. Gubareva, Alexander Klimov, David F. Wurtman, Ronald B. Moss, Maria Hedlund, Jeffrey L. Larson, Robert B. Belshe, Fang Fang> ;Plos One. 2009 Nov 6
• 25 citations
  Prospects for control of emerging infectious diseases with plasmid DNA vaccines
  Ronald B Moss> ;Journal of Immune Based Therapies and Vaccines. 2009 Sep 7
• 7 citations
  Vaccination with cell immunoglobulin mucin-1 antibodies and inactivated influenza enhances vaccine-specific lymphocyte proliferation, interferon-γ production and cross...
  W. Soo Hoo, E. R. Jensen, A. Saadat, D. Nieto, Ronald B. Moss, Dennis J. Carlo, T. Moll> ;Clinical and Experimental Immunology. 2006 Jul 1
• 49 citations
  Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma.
  Jeffrey A. Encinas, Edith M. Janssen, David B. Weiner, Sandra A. Calarota, Daisy Nieto, Thomas Moll, Dennis J. Carlo, Ronald B. Moss> ;The Journal of Allergy and Clinical Immunology. 2005 Dec 1
• Enhanced HIV-1 specific immune response by CpG ODN and HIV-1 immunogen-pulsed dendritic cells confers protection in the Trimera murine model of HIV-1 infection.
  Ayash-Rashkovsky, M.,Borkow, G.,Davis, H. L.,Moss, R. B.,Moss, R. B.,Bartholomew, R.,Bentwich, Z.> ;FASEB J. 2005 Jul
• 41 citations
  CD8+ T-Cell-Mediated Cross-Clade Protection in the Genital Tract following Intranasal Immunization with Inactivated Human Immunodeficiency Virus Antigen Plus CpG Oligo...
  Janina Q. Jiang, Amy J. Patrick, Ronald B. Moss, Kenneth L. Rosenthal> ;Journal of Virology. 2005 Jan 1
• 9 citations
  Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhes...
  Peter Silvera, Jay R. Savary, Virginia Livingston, Jessica A. White, Kelledy Manson, Michael H. Wyand, Peter L. Salk, Ronald B. Moss, Mark G. Lewis> ;Vaccine. 2004 Dec 21
• 67 citations
  Th1/Th2 cells in inflammatory disease states: therapeutic implications.
  Ronald B. Moss, Thomas Moll, Mohammad El-Kalay, Connie Kohne, William Soo Hoo, Jeffrey A. Encinas, Dennis J. Carlo> ;Expert Opinion on Biological Therapy. 2004 Dec 1
• Welcome to the Journal of Immune Based Therapies and Vaccines (JIBTV)
  Ronald B Moss> ;Journal of Immune Based Therapies and Vaccines. 2003 Nov 6
• 8 citations
  Non-viral human IL-10 gene expression reduces acute rejection in heterotopic auxiliary liver transplantation in rats.
  In Chul Hong, Patricia M. Mullen, Andrew F. Precht, Ajai Khanna, Melissa Li, Cynthia Behling, Valerie F. Lopez, Henry C. Chiou, Ronald B. Moss, Marquis E. Hart> ;Microsurgery. 2003 Oct 1
• 14 citations
  HIV-specific immunity during structured antiviral drug treatment interruption
  Ronald B. Moss, Carolyn Brandt, Wieslawa K. Giermakowska, Jay R. Savary, Georgia Theofan, Maurizio Zanetti, Dennis J. Carlo, Mark R. Wallace> ;Vaccine. 2003 Mar 7
• Join now to see all